Cargando…

P1108: HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

Detalles Bibliográficos
Autores principales:	Fried, S., Besser, M. J., Shkury, E., Yerushalmi, R., Shem-Tov, N., Danylesko, I., Jacoby, E., Itzhaki, O., Shouval, R., Kedmi, M., Shimoni, A., Nagler, A., Avigdor, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430686/ http://dx.doi.org/10.1097/01.HS9.0000847300.61295.fe

Ejemplares similares

P520: POINT OF CARE CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH ABERRANT CD19 ANTIGEN EXPRESSION
por: Danylesko, Ivetta, et al.
Publicado: (2023)

P889: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSE/REFRACTORY MULTIPLE MYELOMA
por: Magen, Hila, et al.
Publicado: (2023)

P1400: THREE YEARS OUTCOMES OF PRIMARY MEDIASTINAL B CELL LYMPHOMA PATIENTS FOLLOWING ANTI CD19 CAR-T CELL THERAPY - A SINGLE CENTER EXPERIENCE
por: Geva, Mika, et al.
Publicado: (2023)

Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022)

Reassessing the role of high dose cytarabine and mitoxantrone in relapsed/refractory acute myeloid leukemia
por: Canaani, Jonathan, et al.
Publicado: (2020)

Immunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemia
por: Varda-Bloom, Nira, et al.
Publicado: (2016)

Impact of cryopreservation on CAR T production and clinical response
por: Brezinger-Dayan, Karin, et al.
Publicado: (2022)

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
por: Beider, Katia, et al.
Publicado: (2022)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
por: Rozenbaum, Meir, et al.
Publicado: (2020)

Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions
por: Danylesko, Ivetta, et al.
Publicado: (2012)

1108. Evaluation of Vancomycin Dosing in Adolescents
por: Weaver, Ashley I, et al.
Publicado: (2021)

Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis
por: Eshel, Adi, et al.
Publicado: (2022)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

The CDC42 effector protein MRCKβ autophosphorylates on Threonine 1108
por: Unbekandt, Mathieu, et al.
Publicado: (2019)

P1108: EFFICACY OF PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: RESULTS FROM THE PHASE 1/2 BRUIN STUDY
por: Scarfò, Lydia, et al.
Publicado: (2023)

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders
por: Magen, Hila, et al.
Publicado: (2023)

PB1809: CLINICAL TRAJECTORY OF LONG-TERM SURVIVORS OF ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE INDUCTION CHEMOTHERAPY
por: Heering, G., et al.
Publicado: (2022)

Climatic and societal impacts of a “forgotten” cluster of volcanic eruptions in 1108-1110 CE
por: Guillet, Sébastien, et al.
Publicado: (2020)

Efficacy, safety, and cost-minimization analysis of axicabtagene ciloleucel and tisagenlecleucel CAR T-Cell therapies for treatment of relapsed or refractory follicular lymphoma
por: Ghanem, Buthainah
Publicado: (2023)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

Treatment selection for patients with relapsed or refractory follicular lymphoma
por: Skarbnik, Alan Z., et al.
Publicado: (2023)

The Emerging Role of CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
por: Meier, Jeremy A., et al.
Publicado: (2022)

SG-APSIC1108: Implementation of infection prevention and control in Indonesian hospitals: Identification of strengths, gaps, and challenges in current practices
por: Supriadi, Indri Rooslamiati, et al.
Publicado: (2023)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Determinación del calor de combustión de diferentes materiales, mediante la bomba calorimétrica PARR 1108. : /
por: Román Sánchez, Oscar Daniel
Publicado: (2009)

1108. Diagnostic Yield of the BioFire FilmArray Gastrointestinal Panel in Hospitalized Children at an Academic Children’s Center
por: Madigan, Theresa, et al.
Publicado: (2018)

Recent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
por: Pongas, Georgios, et al.
Publicado: (2021)

Radioiodine Refractory Follicular Thyroid Cancer and Surgery for Cervical Relapse
por: Chiapponi, Costanza, et al.
Publicado: (2021)

1108. Transplantation and Immigration: Comparing Infectious Complications Between Foreign-born vs. U.S.-born Kidney Transplant Recipients in Minnesota
por: Espinoza, Eloy E Ordaya, et al.
Publicado: (2020)

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
por: Trněný, Marek, et al.
Publicado: (2023)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

Correction: Yamamoto, Y.; Gerbi, S.A. Development of Transformation for Genome Editing of an Emerging Model Organism. Genes 2022, 13, 1108
por: Yamamoto, Yutaka, et al.
Publicado: (2023)

Historical Pedigree Reconstruction from Extant Populations Using PArtitioning of RElatives (PREPARE)
por: Shem-Tov, Doron, et al.
Publicado: (2014)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

CAR NK Cell Therapy for T Follicular Helper Cells
por: King, Cecile
Publicado: (2020)

Tu1108: INTERVAL CANCERS IN PATIENTS WITH HEREDITARY GASTROINTESTINAL SYNDROMES AFTER ONE YEAR OF THE SARS-COV-2 PANDEMIC
por: Barchi, Alberto, et al.
Publicado: (2022)

Improved CAR-T cell activity associated with increased mitochondrial function primed by galactose
por: Gross, Golda, et al.
Publicado: (2023)

Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022)

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
por: Mensah, Felix A, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6qvg0trbbtrq591qbth9g6u8v4